Oncimmune has signed a commercial partnership in Russia

Oncimmune Holdings announced an exclusive commercial partnership with R-Pharm JSC to use its EarlyCDT Lung for early lung cancer testing in Russia and member countries of the Eurasian Customs Union (Belarus, Kazakhstan, Armenia and Kyrgyzstan).
Under the terms of the agreement, Oncimmune has authorized R-Pharm to extend the use of EarlyCDT Lung to the countries of the Union of Independent States of Azerbaijan, Turkmenistan, Tajikistan, Ukraine, Uzbekistan and Georgia.
The five-year initial term is intended to generate income of at least ￡5 million, including an advance of ￡2.75 million during this period. R-Pharm will commercialize EarlyCDT Lung in lung cancer screening and tuberculosis risk assessment in the region.
Dr Adam M Hill, Chief Executive Officer of Oncimmune, commented: "Russia has great potential as a screening market with a large number of high-risk populations. After successful ECLS research, this partnership further highlights the growing international acceptance of EarlyCDT Lung as a screening device for early stage lung cancer.
added, "He is pleased to have Alexey and his team at R-Pharm join us to unlock the potential for screening in Russia and further expand the commercial reach of our EarlyCDT portfolio." Russia
38 million smokers, the highest number in Europe. More than 60,000 cases of lung cancer were diagnosed and about 55,000 deaths were reported in 2018. R-Pharm's strategic intention is to maximize the value of EarlyCDT Lung in Moscow's new screening program and ultimately throughout Russia.
The company will promote the registration of local products for the Russian Early CDT Lung, which has already started. (Compiled by this web)